BioInformant

Your Global Leader in Stem Cell Market Research

Home » Coronavirus (COVID-19)

Stem Cell Stocks: A Complete List from “A” to “Z”

By 3 Comments

Biotech investing has become an increasingly popular in recent years. Whether you’re new to stem cell stocks or you’ve been around the block, now could be a good time to place your bets.

The stock market had its largest point drop in recent history on March 9, 2020. On March 12 and March 16, there were two more record-setting point drops. Even though the market has recovered since then, market prices remain attractive across many sectors.

Furthermore, stem cell companies have received substantial support for their use as living therapeutics against COVID-19 induced respiratory complications, such as ARDS. Given these conditions, an intriguing niches within biotech investing is stem cell stocks. [Read more…]

Organicell Receives Approval In Pakistan For The Use Of Zofin™ For Compassionate Grounds For COVID-19

By Leave a Comment

Clinical Trials To Commence Immediately

Miami, FL (May 11, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. [Read more…]

GIOSTAR Launches Subsidiary to Combat COVID-19 and Long COVID

By Leave a Comment

Stem cell research institute seeks to ramp up the charge against global pandemic

SAN DIEGO, May 5, 2021 — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in regenerative technologies, is pleased to announce the formation of GIOCOV. The company – launched in tandem with TAG Investment Bankers LTD of London (TAG) – is a wholly owned subsidiary aimed at delivering stem cell-based treatments for the acute phase of COVID-19, along with the chronic phase (known as Long COVID). [Read more…]

Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19

By 1 Comment

With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.

Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).

In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

By Leave a Comment

Golden, Colorado-April 6, 2021 — Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19.  Our Investigational New Drug (IND) application  will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. [Read more…]

BioInformant's World-Class Clients